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Synopsis
Pseudokinases are classified by the lack of one or several of the highly conserved motifs involved in nucleotide
(nt) binding or catalytic activity of protein kinases (PKs). Pseudokinases represent ∼10% of the human kinome
and they are found in all evolutionary classes of kinases. It has become evident that pseudokinases, which were
initially considered somewhat peculiar dead kinases, are important components in several signalling cascades.
Furthermore, several pseudokinases have been linked to human diseases, particularly cancer, which is raising interest
for therapeutic approaches towards these proteins. The ATP-binding pocket is a well-established drug target and
elucidation of the mechanism and properties of nt binding in pseudokinases is of significant interest and importance.
Recent studies have demonstrated that members of the pseudokinase family are very diverse in structure as well
as in their ability and mechanism to bind nts or perform phosphoryl transfer reactions. This diversity also precludes
prediction of pseudokinase function, or the importance of nt binding for said function, based on primary sequence
alone. Currently available data indicate that ∼40% of pseudokinases are able to bind nts, whereas only few are able
to catalyse occasional phosphoryl transfer. Pseudokinases employ diverse mechanisms to bind nts, which usually
occurs at low, but physiological, affinity. ATP binding serves often a structural role but in most cases the functional
roles are not precisely known. In the present review, we discuss the various mechanisms that pseudokinases employ
for nt binding and how this often low-affinity binding can be accurately analysed.
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INTRODUCTION
In their landmark paper in 2002, Manning and colleagues presen-
ted for the first time a comprehensive catalogue of human protein
kinases (PKs) [1]. One of the salient findings of their analysis
was that ∼10 % of the 518 human PKs lack at least one of the
classical conserved catalytic residues described by Hanks et al.
[2]: the β3 lysine (K in the ‘VAIK’ consensus motif, Figure 1),
the catalytic aspartate (D in ‘HRD’) or the cation-binding as-
partate (D in ‘DFG’). Some of these kinases, like the WNK
(‘With no lysine’) family, were already known to have phos-
phoryl transfer activity despite the lack of canonical catalytic
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Abbreviations: ADCK, aarF domain-containing protein kinase; AMP-PNP, adenylate-imidodiphosphate; ANK, ankyrin repeat domain (in RNase L); ANPa/ANPb, atrial natriuretic peptide
receptor type A/B, also known as atrial natriuretic peptide receptor 1 (NPR1) and NPR2, respectively. Also known as GC-A/GC-B; ATPγS, adenosine 5′ -[γ -thio]triphosphate; BAK1,
BCL2-antagonist/Killer 1; BIR2, BAK1-interacting receptor-like kinase 2; BSK8, brassinosteroid signalling kinase 8; CaM-kinase, Ca2 + /calmodulin-dependent protein kinase; CASK,
calcium/calmodulin-dependent serine protein kinase; COP1, constitutive photomorphogenesis protein 1; EGFR, epidermal growth factor receptor; ePK, eukaryotic protein kinase; GC,
guanylate cyclase; GUCY2, guanylate cyclase, e.g. GUCY2C, also known as GC-C, and heat stable enterotoxin receptor (HSER); HER3, human epidermal growth factor 3, also known as
ERBB3; IRAK, interleukin-1 receptor-associated kinase; ITC, isothermal titration calorimetry; JAK, Janus kinase; JH, JAK homology; LKB1, liver kinase B1; MLKL, mixed lineage kinase
domain-like; nt, nucleotide; NTE, N-terminal extension; PAN3, PAB1P-dependent poly(A)-nuclease; PK, protein kinase; PDZ, protein domain found in PSD95, Dlg1 and zo-1; PKA,
cAMP-dependent protein kinase A; PKD, pseudokinase domain; PKL, protein kinase-like; RIP3, receptor-interacting serine-threonine kinase 3; RLK, receptor-like kinase; ROPK, rhoptry
kinase; ROR, receptor tyrosine kinase-like orphan receptor; RTK, receptor tyrosine kinase; SH3, Src-homology 3 domain; SPR, surface plasmon resonance; STRAD, Ste20-related
adaptor; TK, titin kinase; TLR, Toll-like receptor; TSA, thermal shift assay; VRK, vaccinia-related kinase; WNK, With no lysine.
1 Correspondence may be addressed to either of these authors (email henrik.hammaren@uta.fi or olli.silvennoinen@uta.fi).
sites. Yet, the other 50 identified proteins or protein domains were
deemed likely to be inactive and consequently dubbed ‘pseudok-
inases’. Subsequently, also some of these pseudokinases (like
Haspin) were shown to be catalytically active, and thus could
be reclassified as atypical PKs [3]. For these and some more
recent examples of catalytic activity like KSR2 [4], HER3 [5],
JAK2 JH2 [6] or CASK [7] the distinction of pseudokinase and
atypical kinase has become somewhat unclear. However, as pro-
posed by Eyers and Murphy [8], the bioinformatic definition of a
pseudokinase (with the inclusion of kinases that have experi-
mentally been found to be inactive) should be maintained for
the sake of clarity, and will be used in the present review as
well.
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Figure 1 Conserved motifs and residues contributing to nt binding and kinase activity in (pseudo)kinases
(A) Schematic depiction of the secondary structure elements of ePKs. Relative sizes and positions of elements are
based on PKA (PDB: 4WB5). (B) Sequence alignment of selected pseudokinases and PKL proteins classified based on
current information on nt binding. Conserved PK regions relevant to nt binding are shown. The six highly conserved
residues contributing directly to nt binding or catalytic activity are highlighted. *The gatekeeper residue is not part of the
10 conserved kinase residues identified in [14]. All sequences represent human proteins unless otherwise noted. The
sequence alignment was made using Clustal W [137,138] and manually corrected based on crystal structures and previous
alignments [32,92,139] where available. For non-ePKs the sequences shown are the (predicted) functional/structural
equivalents of the conserved residue in question (secondary structure of e.g. ADCK3 or Fam20 kinases is different from
the one shown in A). Fam20C is included as an example of an active Fam20 kinase. (C) 3D structure of human PKA (PDB:
4WB5) shown as an example of an archetypal ePK. ATP is shown in sticks and the two magnesium cations as purple
spheres. Colours of secondary structure elements are as in (A).
Pseudokinases are spread throughout all PK families [1], in-
dicating that at least most of them have emerged repeatedly from
active kinases throughout evolution. Despite the catalytically in-
active nature of most pseudokinases studied thus far, a recent
survey found that 13 out of the 31 diverse pseudokinases studied
are still able to bind nts [9]. Further studies on the characteristics
and functions of nt binding in pseudokinases have shed light on
this unexpected finding, and shown that pseudokinases employ
diverse mechanisms to bind ATP and suggest that nt binding can
play an important structural and functional role.
Several excellent reviews on the advances in the pseudok-
inase field have been written [3,8,10], including the potential
importance of pseudokinases in human disease [11–13]. Recent
mounting evidence of the importance of the nt-binding site of
pseudokinases in particular, however, warrants a focused discus-
sion on this aspect. The present review aims to provide such
a comprehensive update on the heterogeneity of nt binding in
pseudokinases.
MOTIFS INVOLVED IN NT BINDING IN
PK DOMAINS
Pseudokinases belong to the protein kinase-like (PKL) super-
family which share a conserved fold with an N lobe comprised
mostly of β strands and a mostly α-helical C lobe (Figure 1C).
The catalytic mechanism in PKL proteins involves 10 residues
[14] that are highly conserved even if the proteins may otherwise
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lack sequence conservation [14,15]. Six out of these 10 residues
are directly involved in nt or substrate binding or catalysis [14]
(highlighted in Figure 1B), whereas the function of the remain-
ing four residues is still not completely understood [14], but is
probably mainly structural [16].
The first of the critical residues for nt binding is Gly52 (as
the de facto archetypal protein kinase, human cAMP-dependent
protein kinase A (PKA) is usually used for numbering of amino
acid residues in protein kinase motifs and will also be used in
the present review) in the glycine-rich loop (‘Gly-rich loop’,
also known as the ‘phosphate-binding loop’ or ‘P-loop’) located
between strands β1 and β2 (Figure 1). The function of the Gly-
rich loop is best understood in PKA, in which glycine at this
position enables the peptide backbone of the tip of the loop
(Ser53) to bind the γ -phosphate of ATP. Mutation of the Gly-
rich loop, and especially Gly52, lowers affinity towards ATP and
affects kinase activity [17] as the γ -phosphate can no longer be
efficiently positioned for phosphoryl transfer between the tip of
the Gly-rich loop and a basic residue (Lys168) from the so-called
‘catalytic loop’ situated between β6 and β7 (Figure 1) [18].
Although the function of the Gly-rich loop is well known for
PKA, the motif has not been extensively studied in other kinases
and it is unclear how universal this function is.
The second residue is Lys72 of the ‘VAIK’ motif in β3, which
is the most conserved residue in all PKL proteins, and the only
residue not missing in any of the known families (Figure 1) [14].
Despite its virtually universal conservation and its position next
to the α and β phosphates of ATP (Figure 2, PKA), the function of
Lys72 in nt binding is not entirely clear, and it has been reported to
be dispensable for nt binding in multiple canonical kinases [19–
22]. However, the lysine seems to be required for nt binding in the
pseudokinases GUCY2C [23], HER3 [5], TRIB2 [24] and murine
(and to a lesser extent also human) MLKL [25,26]. Lys72 (or
another lysine in its spatial position, like Lys223, WNK1 in the WNK
family [27]) is absolutely required for catalytic activity both in
multiple canonical kinases [19,20,22], as well as in the low-
activity pseudokinase JAK2 JH2 [6]. Even though its function in
ATP binding is somewhat unclear, Lys72 is critical in making a
salt bridge to the conserved Glu91 in the C helix (αC) (Figure 2,
PKA), thus linking αC to the nt-binding pocket and the helix
in the ‘in’ position, which is a hallmark of the active kinase
conformation [16,28].
The last three of the six conserved residues are required for
catalysis: Asp166 (‘HRD’) and Asn171 in the catalytic loop, and
Asp184 in the ‘DFG’ motif (Figure 1). Asn171 and Asp184 parti-
cipate in the binding of the two divalent cations accompanying
ATP in the canonical mode of ATP binding in kinases (Figure 2,
PKA). Similarly to the β3 lysine, Asp166 and Asp184 are not ab-
solutely required for ATP binding, but rather needed for efficient
catalysis [22], Asp166 being the catalytic base in the phosphoryl
transfer reaction [29].
In addition to these conserved single residues, the purine
pocket of the nt-binding site is lined with a group of hydro-
phobic residues from β2 (Val57) and β3 (Ala70) from the N lobe,
and β7 (Leu173) from the C lobe (Figure 2, PKA). These residues
are part of the so-called ‘catalytic spine’ (C spine), which is a
conserved hydrophobic structure typically found in active kinases
[16,30,31], and which is completed upon binding of a nt’s purine
ring between the N and C lobes (shown in light blue in Figure 2).
Additionally, PKs also have another nonlinear, conserved struc-
tural element called the ‘regulatory spine’ (R spine) [16,30,31],
made up of four residues from DFG, HRD, αC and the αC-β4
loop (shown in beige in Figure 2). This structure is stabilized
by phosphorylation of the activation loop in canonical kinases,
and a fully assembled R spine is usually a prerequisite for kinase
activity [16,30,31].
Functional prediction based on sequences –
exceptions to the rule
The aforementioned conserved residues have been used to pre-
dict nt-binding ability and/or catalytic activity of unknown PKs.
The presence of an intact Gly-rich loop and VAIK motifs, for ex-
ample, seem to have been the best predictors for catalytic activity
in the past [32] – even in noncanonical active kinases like CASK,
which lacks Asp184 but has an intact Gly-rich loop and a β3 lysine.
However, nt-binding ability and mechanisms cannot be reliably
predicted from sequence data alone, as is shown by the innovative
non-canonical nt-binding modes employed by several pseudok-
inases (see below). Thus, accurate biochemical and biophysical
measurements that allow careful differentiation between nt bind-
ing, catalytic activity, and their possible physiological roles, are a
necessity when analysing divergent proteins like pseudokinases.
METHODOLOGY OF MEASURING NT
BINDING
The inherent properties of pseudokinases, i.e. low or absent
kinase activity coupled to unknown nt binding, are often incom-
patible with traditional kinase assays and often multiple methods
and rigorous controls need to be employed in order to obtain reli-
able results. Current techniques, and their challenges with respect
to pseudokinases have been recently described in the excellent
review by Lucet et al. [33]. In order to provide the background
for the following inspection of nt-binding properties in pseudok-
inases, we will highlight some important technical aspects in the
present study as well.
Phosphoryl transfer or ATP hydrolysis activity of pseudok-
inases is generally orders of magnitude lower compared with
active kinases, and therefore even tiny kinase contaminations can
lead to false conclusion of pseudokinase catalytic activity [34].
As an example, in vertebrate mitotic checkpoint protein BUBR1
kinase-inactivating mutations and deletion studies demonstrated
that the initially observed kinase activity was actually derived
from contaminating kinases [35]. Furthermore, as with conven-
tional kinases, choice of substrate can be critical, and the lack
of phosphorylation of a priori likely substrate candidates or an
artificial substrate does not preclude that the protein could have
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Figure 2 Diverse ATP-binding pockets and nt-binding modes among pseudokinases
Crystal structures of ATP-binding pockets of selected representative (pseudo)kinases and PKL proteins with varying
nt-binding modes. Shown are human PKA (PDB: 4WB5), human RNase L (4OAV), human JAK2 JH2 (4FVQ), Arabidopsis
thaliana BSK8 (4I94), human STRADα (3GNI), human VRK3 (2JII), A. thaliana BIR2 (4L68), Rattus norvegicus WNK1 (4Q2A),
human MLKL (4MWI), human ROR2 (4GT4), human TRIB1 (5CEM) and human ADCK3 (4PED). ATP shown in WNK1, MLKL
and ADCK3 was modelled based on PKA (4WB5), as no ATP-bound structures exist, even though they verifiably bind
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specific activity in the context of a physiological protein complex
[8,12].
X-ray crystallography gives atomic-level information on the
structure of a nt-binding pocket and can be used to predict, or in
the case of nt-bound structures, unequivocally verify nt binding.
KSR2 [4], HER3 [5,36], TYK2 JH2 [37], JAK2 JH2 [38], STE20-
related adaptor alpha (STRADα) [39], ILK [40] and CASK [7],
as well as a few other pseudokinases and PKLs from human and
other species, have been crystallized in complex with nts provid-
ing solid proof and mechanistic information of nt binding (see
Table 1). While X-ray crystallography is limited to determination
of rigid protein structures, NMR is applicable for small proteins
(Mr 30–40 kDa [41]) in a soluble state to reveal dynamic struc-
tures [42], and e.g. verify absence or presence of nt binding [43].
Assays measuring nt binding are often less sensitive for low
levels of contaminations than kinase assays. Isothermal titra-
tion calorimetry (ITC) and surface plasmon resonance (SPR) are
quantitative, label-free methods for detection of nt binding. ITC
is the only method for direct measurement of thermodynamic
parameters including enthalpy, Kd and stoichiometry for ligand–
protein interaction, as it directly measures the absorbed or emitted
heat during a (bio)molecular interaction [34]. SPR, on the other
hand, provides direct information about binding kinetics and af-
finity through an optical assay [37,44].
Affinity (and to a lesser extent kinetics) estimates, can also
be obtained using spectrofluorometric assays using intrinsic
fluorescence measurements or fluorescently tagged nts. The in-
trinsic fluorescence method depends on tryptophan, tyrosine
and phenylalanine residue(s), whose spectroscopic character-
istics change in response to nt binding, which makes these
assays somewhat limited in their applicability. More widely-
used fluorescence applications use fluorescent nt analogues in
fluorescence spectroscopy or fluorescence polarization assays.
Mant (2′(3′)-O-(N-methylanthraniloyl)) [5,6,45] and TNP (2′-3′-
O-(2,4,6-trinitrophenyl)) [7,46] are commonly used labels, that
show enhancement in fluorescence once bound to the hydro-
phobic ATP-binding pocket of a (pseudo)kinase. Fluorescence
polarization (also known as fluorescence anisotropy) assays, us-
ing e.g. the long-wavelength fluorescently-labelled BODIPY–
ATP-γ -S nt analogue, measure the increase in fluorescence po-
larization upon binding of a labelled small-molecule ligand to a
protein. Due to its sensitivity, the assay is well-suited for screen-
ing purposes, but it has also been used to assess binding of nt
analogues to pseudokinases [47]. Methods using tagged nts al-
low estimation of the Kd for the nt analogues, but non-specific
binding is possible. Values for unlabelled nts can be estimated by
their ability to displace the fluorescent analogues, which is im-
portant, as the presence of fluorescent tags can change the binding
properties of a nt [39]. For competition experiments the meas-
urement window of the assay is, however, inherently restricted
by the binding affinity of the probe in question.
Binding of nts (or indeed any ligand) to proteins can also
be analysed using thermal shift assays (TSA), which measure
changes in thermal stability of a protein upon binding of ligands.
Changes in thermal stability are measured by observing heat-
induced unfolding of the protein using, e.g. intrinsic fluorescence
of a protein [24,34] or extrinsic fluorescence of a dye [9] as a
readout. Ligand binding generally stabilizes protein structures,
and results in an increased melting temperature (Tm). Correlation
between Tm and Kd or IC50 is dependent on the protein–ligand
pair in question, and TSAs should not be used as a sole method for
Kd determination [48,49]. Furthermore, for low-affinity binders
or cases where ligand binding does not cause large Tm shifts
(Tm), sensitivity can be a problem.
The methods described above are primarily suited for purified
recombinant proteins. Nt affinity chromatography is one of the
few tools for identification of nt binders also from cell lysates.
The method uses affinity beads or immobilized ATP to capture
nt-binding proteins and detection by, e.g. Western blotting [23]
or mass spectrometry in a high-throughput approach [50].
In summary, estimates for nt-binding affinity between different
methods can vary quite significantly, and the choice of method
has to be often determined empirically. In general, label-free
methods, like ITC, should be favoured for accuracy and precision,
but due to limitations in, e.g. protein amount, other assays are also
widely used. Furthermore, the functional role and relevance of
nt binding can rarely be assessed using recombinant proteins
alone, and usually requires site-directed mutagenesis in cellular
assays. Additionally, the modes of nt binding vary widely in
pseudokinases, and they can only be revealed by solving crystal
or NMR structures.
MODES OF NT BINDING IN
PSEUDOKINASES
Given the large variation of pseudokinase sequences especially
at or near the nt-binding site (Figure 1), it is not surprising
that pseudokinases display a wide variety of different nt-binding
mechanisms. The mechanism of ATP binding is currently un-
known in most pseudokinases, but structural information of 21
pseudokinases (Table 1) has shown that pseudokinases can bind
Figure 2 Continued.
adenine nts. ATP or ATP-analogues (e.g. AMP-PNP for BSK8) are shown as sticks with elements coloured as follows:
carbon: black, oxygen: red, nitrogen: blue, phosphorus: orange. Divalent cations are shown as purple spheres. The
halide ion in WNK1 is shown in green. The R spine is shown as a beige volume filling model, whereas the top of the C
spine, encompassing the hydrophobic purine-binding pocket is shown in light blue. Hydrophobic side chains occluding the
purine-binding pocket are shown as part of the C spine for VRK3, BIR2 and ROR2, where the pocket is occluded. Gly-rich
loop glycines are shown as grey spheres with Gly-rich loop side chains omitted, unless of special note. Water molecules
from the crystal structures have been omitted for clarity. *Only one possible conformation given for Gln486, ADCK3 is shown.
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Table 1 Summary of published pseudokinase crystal structures
Abbreviations: P-PCP, β,γ -methyleneadenosine 5′ -triphosphate; AMP-PN, AMP phosphoramidate.
*Crystallized with surface mutations (W659A, W777A, F794H). †Inferred from biochemical data or close homology to published structures showing
the nt-binding mode. ‡Can be made cation-dependent with four point mutations [83]. §Mutated as explained in [77]. ¶Not identical with ROP2
sequence in 2W1Z.
Crystal structures
Protein PDB ID Species Ligand Complex Kd for ATP
Binding
mode Other
KSR2 2Y4I Homo sapiens ATP + Mg MEK1 Unknown 1 cation Active,
phosphorylates
MEK1 [4]
HER3 4OTW H. sapiens Bosutinib – 10− 6 M [5] 1 cation Active, autophos-
phorylates its
own intracellular
region, when
immobilized on
vesicles [5]
4RIW H. sapiens AMP-PNP +
Mg
EGFR KD
(V624R,
F973A,
L977A)
4RIX (Q709R) H. sapiens AMP-PNP +
Mg
EGFR KD
(V624R,
F973A,
L977A)
4RIY (E909G) H. sapiens AMP-PNP +
Mg
EGFR KD
(V624R,
F973A,
L977A)
3KEX H. sapiens AMP-PNP +
Mg
–
3LMG H. sapiens AMP-PNP +
Mg
–
TYK2 JH2 3ZON H. sapiens IKK1 – 10− 5 M [37] 1 cation Inactive [37]
4WOV H. sapiens BMS-066 –
4OLI H. sapiens Inhibitor 7012 JH2-JH1
(D1023N)
5C03 H. sapiens ATPγS + Mg –
5C01 H. sapiens Pyrazine
inhibitor
–
JAK2 JH2 4FVP* H. sapiens – – 10− 6 M [6,45] 1 cation Active, autophos-
phorylates on
S523 and Y570
[6]
4FVQ* H. sapiens ATP + Mg –
4FVR
(V617F)*
H. sapiens ATP + Mg –
JAK1 JH2 4L00 H. sapiens – – 10− 6 M [45] 1 cation† Inactive [65]
4L01 (V658F) H. sapiens – –
MLKL 4BTF Mus
musculus
– – 10− 5 M (TSA)
[26]
No cation†
[9,25,26]
Inactive [25]
4MWI H. sapiens – –
4M67 H. sapiens – –
4M68 M. musculus – –
4M69 M. musculus – RIP3 KD
STRADα 3GNI H. sapiens ATP MO25 10− 4–10− 6 M
[39,82]
No cation
[9]
Inactive [140]
2WTK H. sapiens AMP-PNP MO25 + LKB1
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Table 1 Continued.
Crystal structures
Protein PDB ID Species Ligand Complex Kd for ATP
Binding
mode Other
VRK3 2JII H. sapiens – – None N/A Inactive
ILK 3KMW H. sapiens ATP + Mg α-Parvin 10− 6 M [34] 1 cation Inactive [34,40]
3KMU H. sapiens – α-Parvin
3REP H. sapiens ATP + Mn α-Parvin
CASK 3C0G H. sapiens 3′ -AMP – 10− 3 M [7,9] No cation Active, cations
inhibit binding
and activity.
[7,24,83]
3C0I H. sapiens 3′ -AMP –
3C0H H. sapiens AMP-PNP (only
AMP visible)
–
3TAC H. sapiens – Liprin-α2
3MFS (4M)‡ H. sapiens AMP-PNP –
3MFU (4M)‡ H. sapiens AMP-PNP +
Mn
–
3MFT (4M)‡ H. sapiens – –
3MFR (4M)‡ H. sapiens – –
ROR2 3ZZW H. sapiens – – None [55] N/A Inactive [55,102]
4GT4 H. sapiens – –
BIR2 4L68 Arabidopsis
thaliana
– – None [94] N/A Inactive [94]
BSK8 4I92 A. thaliana – – Unknown 1 cation Inactive [76]
4I93 A. thaliana – –
4I94 A. thaliana AMP-PNP –
Titin 4JNW H. sapiens – – 10− 4 M [113] Unknown Disputed [112–114]
1TKI H. sapiens – –
PAN3 4CYI Chaetomium
thermophi-
lum
ATP + Mg – Unknown, but
probably
rather high
affinity [78]
1 cation Unknown,
physiological role
of PKD is to
shuttle polyribo-
nucleotides to
PAN2 [81]
4CYJ C. thermophi-
lum
ATP + Mg PAN2
4CZY Neurospora
crassa
AMP-PNP +
Mg
PAN2
4BWK N. crassa ATPγS –
4BWX§ N. crassa ATPγS + Mg
4BWP Drosophila
melano-
gaster
AMP-PN –
4XR7 Saccharomyces
cerevisiae
– PAN2
ROP2 2W1Z T. gondii – – None [43] N/A Inactive [43]
3DZO¶ T. gondii Mg –
ROP5B 3Q5Z T. gondii – – Unknown 2 cations Inactive [110]
3Q60 T. gondii ATP + Mg –
4LV5 T. gondii ADP IRGa6 (M.
musculus)
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Table 1 Continued.
Crystal structures
Protein PDB ID Species Ligand Complex Kd for ATP
Binding
mode Other
ROP5C 4LV8 T. gondii ADP + Mg IRGa6 (M.
musculus)
Unknown 1 cation Unknown
ROP8 3BYV T. gondii Mg – Unknown Unknown Unknown
RNase L 4O1O Sus scrofa – 2-5A 10− 3 M [53] 2 cations Inactive [52–54]
4O1P S. scrofa AMP-PNP +
Mg
2-5A
4OAU H. sapiens ADP + Mg 2-5A
4OAV H. sapiens AMP-PCP + Mg RNA + pUp
WNK1 4Q2A Rattus
norvegicus
Br – Unknown Unknown Active [124]
3FPQ R. norvegicus – –
4PWN H. sapiens – –
MviN 3OTV Mycobacterium
tubercu-
losis
– – None [47] Unknown Inactive [47]
3OUK M. tubercu-
losis
– –
3OUN M. tubercu-
losis
– FhaA
3UQC M. tubercu-
losis
– –
ADCK3 4PED H. sapiens – – Binds
preferentially
ADP [108]
Unknown Inactive, can be
activated with a
single Gly-rich
loop mutation
[108]
ATP in a canonical fashion employing two cations or, as in most
cases, in a non-canonical fashion with one or no cations visible in
the crystal structure. In addition, some pseudokinases do not bind
nts at all, and obtain either an active or inactive conformation by
amino acid substitutions and structural rearrangements. Finally, a
recent analysis of 31 pseudokinases showed that some pseudok-
inases were stabilized by the presence of only cations without
nts [9], but the significance of this finding is currently unclear.
In the present study, we provide a comprehensive structural view
on nt binding in pseudokinases with a focus on the nt-binding
mode in pseudokinases for which structural data are currently
available.
Bind nts
PKA
PKA represent the archetype for a canonical PK [51], and its
mode of nt binding is the most prevalent among known PKL
members. PKA binds its nt ligand ATP with two divalent cations
positioned between the phosphates using the critical residues
described above (Figure 2).
RNase L
The only known pseudokinase to date displaying a canonical
nt-binding mode is the mammalian endoribonuclease RNase L.
RNase L functions in the type I interferon (IFN) response where
it is activated by 2′,5′-oligoadenylate (2-5A) second messengers
and cleaves intracellular RNA. RNase L consists of an ankyrin
repeat (ANK), a PK and a RNase domain. Despite its initial
classification as an active kinase [1], the current consensus is
that RNase L is an inactive pseudokinase [52–54], as it does
not autophosphorylate [52], or phosphorylate the generic sub-
strate myelin basic protein (MBP) [54]. The PK in RNase L
is thought to function as a scaffold for homodimerization [54].
RNase L binds ATP with micromolar affinity and ATP binding
activates RNase activity both in vitro and in cells, but is dis-
pensable for RNase L dimerization in the presence of 2-5A [53].
The two recently published crystal structures of human and por-
cine nt-bound RNase L [53,54] show a PK fold with complete
R and C spines resembling the traditional active kinase con-
formation (Figure 2) [31]. The structures, however, also show
a non-canonical C lobe with substitutions in the activation loop
and substrate recognition sites, which probably account for the
inactivity of RNase L [52]. Both solved structures show a fully
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ordered nt in the ATP-binding pocket, which resembles RNase
L’s closest active homologue inositol-requiring protein 1 (IRE1).
Nt binding is coordinated by conserved PK residues, except one
uncommon substitution at Gly186 (Asp505, RNase L), which forms
an additional interaction to one of the cations (Figure 2). The
binding pocket is also flanked by the structured PK-ANK linker,
which participates in 2-5A binding and interdomain interactions
[53,54].
HER3
The most common nt-binding mode among the known pseudok-
inase structures is a one-cation binding mode first seen in hu-
man epidermal growth factor family pseudokinase HER3 (also
known as ERBB3). As with other kinase families, pseudokinases
can also be found in the group of 58 human receptor tyrosine
kinases (RTKs), eight of which have been suggested to con-
tain intracellular pseudokinase domains (PKDs) [55]. Clinically
the most prominent of these is HER3, which mediates cellu-
lar signalling through ligand-induced heterodimerization with
epidermal growth factor receptor (EGFR) and HER2 and al-
losteric activation of their kinase activity [36]. Its clinical rel-
evance is exacerbated by the fact that HER3-mediated HER2-
activation can cause resistance to HER2-targeting cancer ther-
apies [56]. The most noticeable features of the kinase domain
of HER3 are the lack of Glu91 (substituted by His740, HER3, num-
bering as in PDB: 4RIW) and Asp166 (Asn815, HER3), the latter
of which leading to the classification of HER as a pseudokinase
[1,3]. The domain is, however, able to bind ATP tightly with a
Kd of ∼1 μM [5], and several crystal structures with the ATP-
analogue adenylate-imidodiphosphate (AMP-PNP) have been re-
ported (Table 1) [5,36,57], all of which show nt-bound HER3 in
an inactive αC-out conformation. The nt binds together with a
single Mg2 + cation coordinated between the AMP-PNP phos-
phates, Asn171 (Asn820, HER3) and Asp184 (Asp833, HER3). The con-
served β3 lysine (Lys723, HER3) binds to both the α phosphate and
Asp833, HER3 in a non-canonical manner most likely due to the lack
of a Glu91-equivalent in αC. Interestingly, HER3 shows catalytic
trans-autophosphorylation activity in vitro, when immobilized on
vesicles at high local concentrations [5]. The biological relevance
of this is uncertain, however [10,55], as the weak kinase activity
has been reported to be dispensable at least for HER3-mediated
ligand-dependent signalling [55].
JAK JH2
Janus kinases (JAKs) are non-RTKs with a rare domain archi-
tecture containing a pseudokinase (JAK homology 2, JH2) and
a kinase domain (JH1) in tandem. JH2 mediates important reg-
ulatory functions and is needed both for suppression and full
activation of JH1 activity [58–62]. JAKs function in a myriad
of critical biological processes ranging from regulation of the
immune system to haematopoiesis and metabolism [63]. The
identification of multiple disease driver mutations in JAK JH2s
have made them probably the most clinically studied group of
pseudokinases to date. The most prominent of these mutations is
the V617F mutation in JAK2 JH2 underlying multiple myelopro-
liferative neoplasms [64]. While JAK2 JH2 has been shown to
possess low autoregulatory kinase activity [6], JAK1 and TYK2
JH2s are probably catalytically inactive pseudokinases as no auto-
phosphorylation or kinase activity towards exogenous substrates
has been detected [37,65].
Three of the four JAK JH2 domain structures have been solved
over the last few years. The JH2s in all three (JAK1, JAK2, TYK2)
are very similar and show a kinase domain structure with an ac-
cessible nt-binding site, a partially degraded Gly-rich loop (Gly50
and Gly52 are present, however) and an abnormally short activ-
ation loop [37,38,65]. The structures resemble the HER3 PKD
in their nt-binding site architecture, as the canonical Lys72–Glu91
bond is replaced with a Lys72–Asp184 bond and an asparagine sub-
stitutes for Asp166 in the catalytic loop (Figure 1). In JAK2 JH2,
for example, the nt phosphates coordinate around one manganese
cation bound mainly by the conserved Asn171 (Asn678, JAK2). The
phosphates bind between Lys72 (Lys581, JAK2), the Gly-rich loop
backbone at Ser53 (Thr555, JAK2), as well as Lys677, JAK2, which per-
forms the same role as Lys168 but is located two residues down-
stream along the catalytic loop (Figures 1B and 2). Lys677, JAK2
is a lysine or arginine in all JAK JH2s and has been shown to
be essential for ATP binding in JAK2 JH2 [45]. This resembles
tyrosine kinases, which use an arginine at this position to substi-
tute for Lys168 [66]. The hydrophobic lining of the purine-binding
pocket is conserved in all JAK JH2s, including a non-canonically
large aliphatic residue in β3 (Leu579, JAK2).
JAK2 and JAK1 JH2’s bind ATP with micromolar affin-
ity [6,45], whereas the ATP-binding ability of TYK2 JH2 has
been somewhat unclear. In their comprehensive TSA screen of
pseudokinases, Murphy et al. [9], observed a slight positive Tm
shift upon addition of 200 μM ATP to TYK2 JH2, whereas
Tokarski et al. [67] did not observe signs of ATP binding in their
TSA or competition assays. TYK2 JH2 has, however, (along with
JAK1 JH2) been found to be able to bind multiple kinase inhibitor
scaffolds with submicromolar affinity [67,68]. A recent crystal
structure of adenosine 5′-[γ -thio]triphosphate (ATPγ S)-bound
TYK2 JH2 confirms that the domain is indeed capable of bind-
ing ATP. Furthermore, MANT-ATP, SPR and TSA experiments
showed that the domain binds ATP with a Kd ∼15–20 μM [37].
JAK2 JH2 has been found to possess low catalytic activ-
ity that phosphorylates two regulatory residues (S523, Y570)
in JAK2 [6]. Phosphorylation of these residues facilitates the
autoinhibitory interaction between JH1 and JH2 [69,70]. JAK1
and TYK2, however, do not possess kinase activity, despite bind-
ing ATP [37,65]. Comparison of the three JH2 structures shows
that they all contain a helix (αAL) in the activation loop that
in JAK1 and TYK2, but not in JAK2, is stabilized by two salt
bridges and may block the substrate entrance [37]. Furthermore,
S523 and Y570 residues are not conserved in JAK1 and TYK2
and the lack of suitable substrates may also account for the
lack of phosphorylation-mediated regulation that may repres-
ent an ancestral function in JAK JH2 (JAK2 is the ancestral
form).
Crystal structures of apo and ATP-bound forms do not show
major binding-induced changes in TYK2 JH2 [37], and for JAK2
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JH2 only a stabilization of αC has been observed [38,45]. Inter-
estingly, however, recent mutagenesis experiments indicate that
ATP-binding to JAK2 JH2 is critical for the pathogenic activation
of JAK, while being largely dispensable for wild-type functions
[45]. This finding, along with the recent identification of a TYK2
JH2 binding inhibitor able to modulate TYK2 activity [67] make
JAK JH2s tempting pharmacological targets.
KSR2
Kinase suppressors of Ras (KSR) act as a dynamic protein scaf-
fold for signalling complexes in the Ras-Raf-MEK pathway. Both
KSR members, KSR1 and KSR2, have been shown to be catalyt-
ically active pseudokinases [71], with KSR2 being able to phos-
phorylate its binding partner MEK1 [4]. Accordingly, some of
the known KSR2 loss-of-function mutations locate to the ATP-
binding pocket [4]. The only published KSR structure shows
ATP-bound KSR2 in complex with MEK1 (Table 1) [4]. KSR2
binds ATP with a single magnesium ion coordinated canonically
by Asn171 (Asn791, KSR2) and Asp184 (Asp803, KSR2). Despite the
unconventional replacement of the β3 lysine with Arg692, KSR2,
which positions close to Asp184 (Asp803, KSR2) and is reminis-
cent of the Lys72–Asp184 bond in HER3 and JAK JH2s, most
other typical residues in the active site are conserved with Asn171
(Asn791, KSR2) and Asp166 (Asp786, KSR2) in place (Figure 1B). As
a consequence of the Lys72–Asp184 bond, αC in KSR2 is in the
out position. KSR2 presents an enticing therapeutic target [13],
as mutations (some of which locate to the PKD) in KSR2 affect
energy balance and are associated with numerous diseases, like
obesity and related metabolic problems [72].
ILK
Integrin-linked kinase (ILK) is an important mediator of cell
motility and signal transduction by connecting integrin recept-
ors to the actin cytoskeleton. The PKD of ILK binds ATP with
micromolar affinity [34,50], and two crystal structures of ATP-
bound ILK in complex with its interaction partner α-Parvin are
available (Table 1). Both structures show interesting peculiarities
in the ATP-binding mode of ILK. The Gly-rich loop of ILK is
highly divergent, with the conserved glycines Gly50 and Gly52
substituted by Asn200, ILK and Asn202, ILK (Figure 1B). Interest-
ingly, these residues make contacts with the ATP phosphates
with their side chains rather than the peptide backbone [40], as
is usually the case for the Gly-rich loop. Furthermore, the phos-
phates are also coordinated by a noncanonical lysine (Lys341, ILK
substituting Gly186 in the DFG (DVKILK) motif), which lunges
over in the binding site close to the γ -phosphate. The lack of Gly
in the DFG motif also probably locks ILK in a ‘DFG-in’ conform-
ation [40]. The single cation seen between the ATP phosphates is
coordinated solely by Asp184 (Asp339, ILK), as other usually cation-
coordinating residues are substituted by non-canonical residues
(e.g. Asn171 by Ser324, ILK, Figure 1). The unusual binding mode,
which includes binding of the β3 lysine to the α and γ phosphates
(instead of α and β), causes ATP to adopt a binding conforma-
tion not usually seen in kinases, with the γ -phosphate pointing
up towards the N lobe of the domain [40].
Functionally, ATP binding is needed for ILK to interact with
its interaction partner α-Parvin [34,73], even though the observed
effects of ATP on the macromolecular structure and multiple bio-
chemical and biophysical properties are small [34]. The catalytic
(in)activity of ILK has been controversial [74], but evidence from
recombinant and purified ILK as well as the multiple changes in
the active site residues (most critically a lack of the traditional
catalytic base, Asp166), point towards ILK being catalytically in-
active [34,40].
BSK8
Plants rely heavily on receptor kinases in their cellular signalling,
and receptor-like kinases (RLK) constitute one of the largest gene
families in plants [75]. Interestingly, a disproportionately large
percentage of RLKs are predicted pseudokinases. In Arabidopsis,
for example, ∼20 % of ∼600 RLK genes, are predicted pseudok-
inases, whereas the same portion is only ∼13 % in the whole
kinome (totalling ∼1000 kinases) [75]. One of the very few plant
pseudokinases that has received closer attention to date is the
brassinosteroid signalling kinase 8 (BSK8) from Arabidopsis. Its
structure was recently solved with and without AMP-PNP [76].
The structures show a kinase domain with a rather unconven-
tional, enlarged Gly-rich loop that bends into the ATP-binding
pocket when no ligand is bound, but is displaced outwards in
a loop structure that makes room for a Mg2 + ion binding in a
non-canonical manner between the phosphates of AMP-PNP and
the side chain of Asn71, BSK8 (colocalizes structurally with Gly52)
in the Gly-rich loop, which itself is displaced outwards from
the nt-binding pocket (Figure 2). Irrespective of ligand bind-
ing, the rather short activation loop is in a somewhat closed
conformation, and Phe185 from the DFG motif (Phe200, BSK8 in
CFGBSK8) bends deep into the nt-binding pocket and partially
fills out a void in the back of the pocket caused by the unusually
small gatekeeper alanine (Ala132, BSK8). This DFG conformation
is the first of its kind in PKs. Despite its capability to bind ATP,
BSK is most likely an inactive kinase with no detected auto- or
substrate phosphorylation activity [76]. The biological role of the
unusual ATP-binding pocket is thus far unknown.
PAN3
Human PAB1P-dependent poly(A)-nuclease (PAN3) forms a
poly(A)-specific RNase complex together with the exonuclease
PAN2. The active PAN2–PAN3 complex functions in both gen-
eral and miRNA-mediated mRNA deadenylation. PAN3 contains
a dimerization domain and a highly divergent PKD that lacks most
of the typical kinase structures, including a peptide substrate-
binding site, and was not classified as a (pseudo)kinase by Man-
ning et al., [1]. Solving of the structure of the kinase-like domain
of PAN3 still showed a clear PK fold able to bind ATP [77,78].
Furthermore, an intact nt-binding site was required for activation
of the mRNA-targeted exonuclease activity of PAN2 [77,79].
An explanation for this finding has recently been proposed by
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three independent studies [78–80], which all point towards a
common model of PAN2–PAN3-mediated mRNA degradation.
In the model, the highly divergent ATP-binding site of PAN3 ac-
tually functions as a polyribonucleotide-binding domain, which
shuttles RNA to the exonuclease domain of PAN2 [81], thus
providing a striking example of creative use of the nt-binding site
of a pseudokinase scaffold.
STRADα
The STRADα is a pseudokinase that forms a trimeric tumour
suppressor complex together with MO25α and the active protein
threonine kinase LKB1 (liver kinase B1), mutations in which
are linked to various cancers including the Peutz-Jeghers in-
testinal cancer syndrome [11]. STRADα is able to bind ATP
with a micromolar Kd [39,50,82] in a cation-independent man-
ner [39,82]. Structural studies of the STRADα–MO25 complex
[39], as well as the whole ternary complex [46], showed that des-
pite the cation-independence, STRADα binds ATP in a more or
less canonical mode with Arg215, STRADα from GLRSTRADα (DFG)
and His200, STRADα (Asn171) substituting for the cation (Figure 2)
[39]. The conformation of STRADα in the complexes resembles
the active conformation of kinases with an ordered activation
loop and an intact R spine. This conformation enables STRADα
to bind LKB1 in a traditional PK–substrate interaction. Interest-
ingly, even though early mutagenesis data suggested that ATP
binding to STRADα was not needed for its function [82], de-
tailed analysis of the STRADα–MO25 complex in controlling
LKB1 activity has since shown that ATP binding to STRADα
enhances the MO25 interaction in a cooperative manner thus
strengthening LKB1 activation in the STRADα–MO25α–LKB1
complex [39].
CASK
The calcium/calmodulin-dependent serine protein kinase
(CASK) belongs to the membrane-associated guanylate kinase
(MAGUK) protein family, and consists of an N-terminal
Ca2 + /calmodulin-dependent protein kinase (CaM-kinase) do-
main as well as L27, PDZ, SH3, and guanylate kinase domains.
Its biological functions have not been completely elucidated, but
it is known to be involved in synaptic processes during develop-
ment and regulating cell proliferation and behavioural responses
[7,11]. Although initially classified as a pseudokinase [1], the
CaM-kinase domain of CASK is now most commonly classified
as an atypical kinase [7,16,32,83] as it has been shown to be able
to catalyse autophosphorylation and phosphorylation of its sub-
strate Neurexin-l in vitro [7]. Intriguingly, the phosphoryl transfer
activity of CASK is not only cation-independent, but actually in-
hibited by them [7] – a characteristic, which can be reversed by
four point mutations in the ATP-binding pocket, which transform
CASK into a Mg-sensitive kinase [83]. Wild-type CASK binds
ATP weakly (Kd in millimolar range) [7,9], and in the only crystal
structure of wild-type CASK with an ATP analogue (AMP-PNP)
the β and γ -phosphates are disordered and not visible (Table 1).
Despite its unusual binding pocket characteristics, CASK has
been shown to be able to bind multiple known kinase inhibitors,
including, e.g., the pan-kinase inhibitor staurosporine [68].
MLKL
MLKL protein is an evolutionarily interesting pseudokinase that
has critical functions in necroptosis (i.e. death-receptor-initiated
cell death, when execution of apoptosis is prevented), where
MLKL is phosphorylated on its activation loop by the receptor-
interacting serine-threonine kinase 3 (RIP3) [84]. MLKL is an
extremely divergent pseudokinase with noncanonical residues in
the Gly-rich loop, HRD, as well as DFG-motifs (Figure 1B).
Interestingly, the Gly-rich loop and the HRD motif also differ
between mouse and human MLKLs, suggesting relaxed evol-
utionary constraints, or very recently evolved specialized func-
tions [26]. The crystal structures of the murine and human MLKL
kinase domains have been solved independently by two groups
[25,26,85], and show distinctly different conformations between
the species. Human MLKL exhibits the canonical Lys72–Glu91
bond (Lys230, MLKL, Hs–Glu250, MLKL, Hs, Figure 2), yet this bond
is disrupted in murine MLKL where the activation loop forms
a helix in between the β3 lysine and αC [25,26,85]. Although
these structures could represent two conformations of the same
protein, they are also accompanied by rather significant differ-
ences in primary sequence in usually constant motifs (Figure 1B).
Both human and murine MLKL bind ATP, but only in the
absence of cations, which is in line with the altered cation-
binding residues in the pseudoactive site [25,26]. Of the pre-
sumed ATP-binding residues, human and murine MLKL only
share Lys72 [25,26], and even here, the need for lysine at this pos-
ition is not absolute in human MLKL, as Lys331, MLKL, Hs from the
HRD (HGKMLKL, Hs) motif can contribute to ATP binding [26]. In
murine MLKL this residue is Asn318, MLKL, Mm, and the need for
the β3 lysine for ATP binding is absolute [25].
The ATP-binding ability does not seem to be needed for the
physiological role of (at least murine) MLKL, as probed with K-
to-M mutations of the β3 lysine [25]. Interestingly, however,
overexpression of murine MLKL pseudoactive site (K219M,
Q343A) or phosphomimicking activation loop mutants (S345D)
in MLKL− / − cells caused cell death even without stimulation,
suggesting that changes in the pseudoactive site could mimic the
activation of MLKL by RIP3 [25].
Guanylate cyclases
Another interesting group of pseudokinase-containing proteins
are the membrane guanylate cyclases [pGC for particulate
guanylate cyclase (GC); five members in humans: atrial natriur-
etic peptide receptor type A (ANPa), atrial natriuretic peptide re-
ceptor type B (ANPb), GUCY2C, GUCY2D and GUCY2F] that
produce the second messenger cyclic GMP (cGMP) from GTP.
PGCs are transmembrane proteins with an extracellular ligand-
binding domain and an intracellular PKD next to the catalytic
GC domain. Interestingly, the PKD seems to have a functional
ATP-binding site exhibiting β3 lysine-dependent ATP binding
[23,86]. This binding site in the PKD was originally considered
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to be the allosteric site causing the well-known ATP-sensitivity of
GC catalytic activity [87]. Recently, however, Robinson and Pot-
ter [88] showed that the ATP-binding site exerting the allosteric
regulation site is, in fact, most likely in the catalytic domain itself.
According to their model, two pGC catalytic domains form an
asymmetric dimer upon activation, and the nt-binding site of one
domain acts as the allosteric ATP-binding site, whereas the other
acts as the catalytic site binding substrate GTP [88]. Intriguingly,
this leaves the pGC PKDs with functional ATP-binding sites
without a known physiological function.
Fam20A
A very recently identified pseudokinase, Fam20A (family with
sequence similarity 20, member A), is found in the secretory path-
way. Although phosphorylated secreted proteins (like casein) had
been known for well over a century, the kinases responsible for
these phosphorylations had remained elusive until very recently
[89]. The atypical PK Fam20C was identified as the physiolo-
gical kinase responsible for phosphorylating not only casein [90]
but actually the vast majority of all secreted phosphoproteins in
humans [91]. In some tissues, like dental tissues and the lactat-
ing mammary gland, secreted protein phosphorylation seemed to
be activated by a closely related paralog, Fam20A, also implic-
ated in biomineralization along with Fam20C [92]. Interestingly,
Fam20A is a pseudokinase unable to catalyse phosphotransfer or
ATP hydrolysis itself, due to the critical Asp184 being exchanged
by Gln258, Fam20A (Figure 1B) [92]. Careful examination showed
that Fam20A coexpresses and directly interacts with Fam20C,
resulting in activation of Fam20C catalytic activity by increasing
kcat and decreasing Km [92]. This activation was inhibited by the
presence of known Fam20A disease mutations [92], which most
likely act by disrupting the structural integrity of the protein [93].
Despite lacking catalytic activity, Fam20A was found to be able
to bind ATP in a TSA, and back-mutating the only non-canonical
critical residue (Gln258, Fam20A) to a more canonical acidic residue
(Glu) restored catalytic activity [92]. Simultaneously, however,
the Fam20A(Q258E) mutant showed slightly reduced ability to
activate Fam20C activity, which the authors speculate might be
due to a lack of permanent occupation of the ATP-binding pocket
of Fam20A [92]. Whether this is the case, and ATP-binding to
Fam20A is critical for its ability to activate Fam20C remains to
be clearly shown.
No nt binding
VRK3
The vaccinia-related kinase (VRK) family consists of three ver-
tebrate members, two of which are active kinases (VRK1–2) and
one (VRK3) a pseudokinase. VRK3 was one of the first pseudok-
inases with a published crystal structure [32], and it showed a
kinase fold locked in a rather stable ‘pseudoactive’ conformation
with the N and C lobes closed, αC rotated inwards, Lys72–Glu91
(Lys203, VRK3–Glu214, VRK3) intact, and a fully formed R spine as-
sembled (Figure 2). Strikingly, the ATP-binding site of VRK3 is
inaccessible as the purine-binding pocket is filled with large hy-
drophobic side chains (Phe313, VRK3, Leu262, VRK3 and Leu180, VRK3)
thus completing the C spine without a bound nt (Figure 2). Fur-
thermore, the severely degenerated Gly-rich loop extends side
chains [Thr173, VRK3 (Gly50) and Asp175, VRK3 (Gly52)] into the
pocket, thus precluding nt binding completely. Correspondingly,
VRK3 does not show binding of nts or nt-analogues in TSAs
[9,32]. VRK3 is a prime example how sequence conservation
can be ‘inverted’ in pseudokinases, as the catalytic site is very
poorly conserved with many substitutions (Figure 1B), yet parts
of the molecular surface are highly conserved probably repres-
enting key protein–protein interaction regions [32].
BIR2
A pseudokinase clearly shown to adopt an αC-out conformation
in conjunction with a blocked ATP-binding pocked is BCL2-
antagonist/Killer 1 (BAK1)-interacting receptor-like kinase 2
(BIR2) from Arabidopsis. BIR2 belongs to the leucine-rich re-
peat (LRR) RLKs, which comprise about one third of all Ar-
abidopsis RLKs, and whose kinase domains share a common
origin with the Drosophila Pelle and human IRAKs (interleukin-
1 receptor-associated kinases) [94]. The crystal structure of the
BIR2 cytosolic portion shows a kinase domain with a mostly
occluded nt-binding site. This is mainly caused by a downward
shifted conformation of the Gly-rich loop backbone as well as
bulky side chains protruding into the binding site (e.g. Ile313, BIR2,
Val314, BIR2, Thr316, BIR2 corresponding to Leu49, Gly50 and Gly52).
These side chains form a rigid hydrophobic network extend-
ing all the way to the catalytic loop Val434, BIR2 (Asn171) (Fig-
ure 2), thus precluding binding of nts or nt analogues, as also
verified with NMR [94]. αC of BIR2 is in the typical ‘out’ po-
sition, with a short helix (αAL in Figure 2) formed from the
activation loop after the DFG motif (DSGBIR2) taking position
between αC and the occluded nt-binding site. This conformation
is further strengthened by a Lys72–Asp184 salt bridge (Lys335, BIR2–
Asp447, BIR2). The blocked nt-binding site together with the inact-
ive conformation make BIR2 probably a catalytically inactive
pseudokinase, which interacts constitutively with its target of
regulation, BAK1 [94]. The large amount of BAK1 phosphoryla-
tion sites on BIR2 have brought forth the hypothesis that BIR2
might regulate BAK1 by acting as a ‘dummy substrate’ for it
[94].
ROR2
In addition to HER3, there is currently only one other published
structure of a human RTK PKD: ROR2, or receptor tyrosine
kinase-like orphan receptor 2. Despite its name, the ROR fam-
ily (comprising ROR1 and ROR2 in vertebrates) is now known
to function as receptors for several Wnt ligands [95]. ROR2’s
biological functions are mainly in early embryonic develop-
ment, although recent evidence has shown ROR2 expression
to be up-regulated in many cancers, making ROR2 a poten-
tial drug target [96]. Catalytic activity of ROR2 is controver-
sial [55,96]. Both ROR1 and ROR2 were predicted to be active
[1] as the primary sequences include all catalytic residues (with
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the exception of Gly52, Figure 1B), and even two Tyr residues
in the activation loop. Also, numerous groups have reported
(auto)phosphorylation of ROR2 from immunoprecipitated ex-
tracts [97–101]. However, whether the apparent catalytic activity
stems from interacting kinases or ROR2 itself is in most cases un-
clear [96]. Efforts using purified recombinant ROR1 and ROR2
cytoplasmic portions, including the kinase domains, have thus
far been unable to detect catalytic activity [102] or nt binding
[55].
The two published crystal structures of the ROR2 kinase do-
main (Table 1) show the domain in an inactive, DFG-out, con-
formation which resembles the inactive conformation of IRK (in-
sulin receptor kinase) [103], where the activation loop bends into
the nt-binding pocket occupying the position of the nt phosphates
(Figure 2) [104]. However, the inactive ROR2 conformation dif-
fers from the canonical IRK-like conformation in three ways.
Firstly, the adenine-binding pocket is occluded by Tyr555, ROR2
from the hinge region, which adopts an uncommon conform-
ation (Figure 2), possibly making up for the unusually small
Leu634, ROR2 (Phe185) from the DLG (DFG) motif in blocking
the adenine pocket [55,104]. Secondly, Leu636, ROR2 blocks the
phosphate-binding pocket causing Asp633, ROR2 (Asp184) to move
closer to αC and thus (thirdly) enabling a direct salt bridge link
to an Arg residue in αC (Arg528, ROR2), thus presumably further
stabilizing the inactive conformation [104]. Although the DFG-
αC link is not observed in all solved ROR2 structures, the first
two are most likely sufficient to block out nts and explain the lack
of binding [55]. Interestingly, however, the prominent role of the
unusual conformation of Tyr555, ROR2 in occluding the nt-binding
pocket has been suggested to potentially enable activation of
ROR2 via phosphorylation of this residue [55,104]. This hypo-
thesis remains yet to be tested, however.
Variable binding modes and abilities, or nt binding
undefined
TRIBs
There are four mammalian pseudokinases related to the Droso-
phila Tribbles: TRIB1–3 and SgK495 [24]. All TRIBs are linked
to various forms of cancer [11], and they represent an interesting
group of pseudokinases with a myriad of implicated biological
functions [24,105,106], and possible therapeutic potential [13].
TRIBs 1–3 consist of variable N-terminal extensions (NTEs),
a highly conserved PKD and a C-terminal extension including
a conserved region for binding the E3 ligase constitutive pho-
tomorphogenesis protein 1 (COP1) [105]. This COP1-binding
domain seems critical for the physiological function of TRIBs,
and the current model is that TRIBs act as scaffolds recruit-
ing target proteins using their PKD, and linking them with COP1
for ubiquitination [105,107]. TRIB pseudokinases have degraded
acidic motifs in place of the Gly-rich loop [24], and highly non-
canonical deviations in the DFG motif (e.g. SLETRIB1 and TRIB2,
Figure 1B). The drastic structural consequences of these changes
were revealed recently by Murphy et al. [105], who managed
to solve the crystal structure of human TRIB1 thus generating
the first structure of a Tribbles protein. The structure shows a
kinase-like fold with a traditional C lobe, but a highly altered N
lobe. The degraded Gly-rich loop is short and contains a bend-
inducing proline (Pro98, TRIB1) causing the whole loop (normally
forming the top of the nt-binding pocket) to be in a retracted posi-
tion. TRIB1 also exhibits a shortened αC along with a practically
non-existent β3-αC loop, which locks αC into a distorted, bent
conformation (Figure 2) [105]. Additionally, the noncanonical
DFG motif (SLETRIB1, Figure 1B) is in a conformation resem-
bling the ‘DFG-out’ state [28] (Figure 2). This unusual configura-
tion seems to be stabilized by multiple salt bridges, including the
β3 lysine (Lys120, TRIB1) connecting to the Leu226, TRIB1 backbone
(there is no Glu91 homologue in αC) and Lys210, TRIB1 (Asn171)
connecting to Glu224, TRIB1, which precedes the SLE motif and is
unique among human kinases [105]. Lys210, TRIB1 is itself stabil-
ized by the catalytic aspartate Asp205, TRIB1 (Asp166). All of these
factors combine to form a wide, yet obstructed, ATP-binding
pocket incompatible with nt binding – a conclusion backed up by
TSA measurements showing no observable nt binding for TRIB1
[105].
Despite sharing over >70 % amino acid sequence identity
with TRIB1, TRIB2 has, in contrast, been shown to exhibit sig-
nificant Tm shifts in intrinsic fluorescence and TSA at 1 mM
ATP in the absence of cations [24], and slight Tm shifts at
200 μM ATP [9], indicative of relatively weak ATP binding
[24]. Furthermore, TRIB2 and TRIB3 have both been reported to
show low cation-independent autophosphorylation activity, but
the biological significance of this is unclear [24]. Murphy et
al. [105] speculate that this difference could be due to a crit-
ical alteration (Tyr134, TRIB1 is Cys104, TRIB2) in the TRIB2 C helix
that could enable the SLETRIB1 and TRIB2 motif to acquire a more
DFG-in-like state, thus enabling nt binding. Interestingly, muta-
genesis experiments in cells have shown that an intact ATP-
binding pocket is needed for the transforming ability of TRB2
[107].
ADCK3
Most of PK research has focused on eukaryotic protein kinases
(ePKs), and approximately half of the 20 PKL families are yet to
be structurally explored [14]. One of those families, the evolu-
tionarily ancient UbiB family, recently had its first protein struc-
ture solved, with the crystal structure of human aarF domain-
containing protein kinase (ADCK)3 [108], a mitochondrial pro-
tein involved in isoprenoid lipid metabolism. The human ADCK
family (comprising ADCK1–5) had been classified as an ‘atyp-
ical kinase’ [1], but experimental validation of enzyme activity
remained elusive [108]. The structure shows a conserved core PK
fold with a C lobe insert and two additions to the N lobe from
conserved UbiB-specific features: an NTE before β1 (helices
GQα1–4), and an insert between β3 and αC (GQα5–6, Figure 2).
UbiB proteins also share a striking alteration in the Gly-rich loop,
which is replaced by an Ala-rich loop. The NTE and the N-lobe
insertion both form α helices that fold on to the Ala-rich loop and
peptide substrate-binding cleft. Specifically, a conserved KxGQ
motif from the NTE and a conserved ExD motif (Glu405, ADCK3)
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from the N lobe insertion fold into the active site of the pro-
tein (Figure 2) leaving the substrate-binding pocket completely
occluded. Also, catalytic activity seems to be further prohib-
ited as the catalytic Asp166 (Asp488, ADCK3) points away from the
active site towards αF, where it makes a double salt bridge to
Arg611, ADCK3 (Figure 2) – a residue strictly conserved as either
arginine or lysine in the UbiB family [108]. Despite these al-
terations, however, all traditional catalytic residues are present
(Figure 1B), the Lys72–Glu91 (Lys358, ADCK3–Glu411, ADCK3) salt
bridge is visible, and the regulatory spine is intact. Furthermore,
Stefely and colleagues could show that ADCK3 was stabilized
by nts in a TSA, but with a striking preference towards ADP
over ATP [108]. Careful mutagenesis studies further showed that
this preference could be reversed by a single mutation restor-
ing Gly52 (Ala339, ADCK3) to the Ala-rich loop [108]. Additionally
the A339GADCK3 mutation also enabled Mg-ATP-mediated auto-
phosphorylation, which was enhanced by removal of the KxGQ
motif from the NTE, clearly demonstrating that the domain has
catalytic potential, but is inhibited by its preference for ADP over
ATP and the inhibitory insertion into the active site. Intriguingly,
these regions inhibiting kinase activity were also critical for the
physiological function of the yeast ADCK3 homologue Coq8p
in vivo [108]. Whether this means that ADCK3 is truly a pseudok-
inase, or whether it is a PK that is activated through interactions
with other proteins is currently unclear. Stefely and colleagues
put forward a further hypothesis, proposing that ADCK3 would
not be a PK after all, but rather could be able to phosphorylate
small molecules, like lipids, which might still be able to bind to
the substrate-binding pocket despite the NTE [108].
ROPKs
An interesting group of pseudokinases outside of vertebrates is
the rhoptry kinase (ROPK) family of apicomplexans – a phylum
of parasitous protists including, e.g. Toxoplasma gondii, in which
roughly one third of all kinases are ROPKs. Many ROPKs are
key virulence factors and they are exported into the parasite’s
host cell during infection, where they assist in transforming the
host cell environment to a more permissive state for the para-
site [109]. Roughly half of the 42 known ROPK subfamilies are
pseudokinases [109], and ROPK genes are often found in expan-
ded loci that are likely sites of local tandem duplication with high
sequence polymorphism [110]. Furthermore, members of ROPK
subfamilies probably acquired the inactivating changes individu-
ally, thus repeatedly generating new and varying pseudokinases
[109]. Thus far, four ROP pseudokinase structures have been
published (Table 1): ROP2 [43], ROP8 [111], ROP5B [110] and
ROP5C (PDB: 4LV8, Reese M.L., Boothroyd J.C., unpublished
work). All ROPKs have a common NTE subdomain, which loops
around the N lobe and down next to the hinge towards the C lobe.
This extension has been hypothesized to be a regulatory region
phosphorylated by active ROPKs, such as the key virulence factor
ROP18 [111]. In the case of ROP2 and ROP8, the NTE runs over
the nt-binding site inserting a large side chain (Trp215, ROP2 [43],
Arg228, ROP8 [111]) into the site, thus precluding ATP binding.
Accordingly, most of the residues in and around the nt-binding
site are highly variable among a subset of ROP2-like kinases
(including ROP8), suggesting lack of evolutionary pressure as
can be expected for a catalytically inactive pseudokinase [43].
Interestingly, however, there are still some sequence motifs in
the pseudoactive sites of ROPKs, which many pseudokinases
have converged to. Namely, a change of the HRD motif to HGX,
where X is often a basic residue (e.g. HGHROP5B and C) [110]. Sim-
ilar converging substitutions are also seen in the human kinome,
where 19 out of ∼50 human pseudokinases have the R-to-G sub-
stitution, whereas it is seen in only 8 out of the ∼500 active
human kinases [110].
Despite changes in the nt-binding region, the peptide-binding
site of ROP2 and ROP8 seem rather conserved, suggesting that
these proteins might still be capable of kinase–substrate-like
interactions [43]. As another example of the extensive hetero-
geneity among ROPKs is ROP5, which, although able to bind
ATP, is probably inactive [110]. Structural analysis of ROP5B re-
vealed a noncanonical mode of ATP binding with two magnesium
ions unusually coordinated between the ATP phosphates. Despite
the conservation of Asn171 (Asn394, ROP5B) the residue next to it
(Asp393, ROP5B) actually takes its place in coordinating the ions.
Furthermore, Asp184 (Asp407, ROP5B) is shifted towards αC and
only coordinates one of the bound Mg ions compared with the
two in the canonical mode of binding. Also, a basic side chain
connecting the γ -phosphate usually provided from the catalytic
loop (Lys168) seems to be substituted for by Arg245, ROP5B from the
Gly-rich loop in ROP5B [110]. ROP5B also shows other features
more commonly seen in other pseudokinases, like the lack of a
correctly oriented Glu91 analogue, and thus a possible salt bridge
between the equivalents of Lys72 and Asp184 (as seen in the JAK
JH2s, HER3 and KSR2).
Titin
An example of a protein where the kinase/pseudokinase de-
bate has taken a recent turn, is the giant myofilament protein
titin (Mr up to 4.2 MDa) found in sarcomeres. Titin contains
over 200 immunoglobulin- or fibronectin type-III-like domains
(actual numbers depend on the isoform in question) as well as
a kinase domain (titin kinase, TK) near its C-terminus. TK con-
sists of a mostly canonical kinase domain with a C-terminal
insertion folding into its active site thus effectively blocking po-
tential activity [112]. Early results suggested that TK could be
activated by removal of the blocking C-terminal extension and
simultaneous tyrosine phosphorylation of the activation loop, and
that TK could phosphorylate telethonin/Tcap [112]. More recent
single-molecule experiments indicated, that TK was able to bind
ATP (rather weakly, Kd ∼350 μM), but only when mechanic-
ally stretched, possibly due to removal of the C-terminal exten-
sion from the active site [113]. Titin’s position as a mechano-
sensitive, active kinase has, however, been recently questioned,
as the telethonin/Tcap-phosphorylating kinase activity in insect
cell preparations was shown to be likely due to a contam-
inating kinase [114], as bacterially produced TK lacks activ-
ity [113,114], and the telethonin/Tcap-phosphorylating kinase
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activity does not strictly copurify with recombinant TK [114].
Furthermore, two noncanonical substitutions in TK’s VAIK and
DFG motifs (Y/FMAK and EFG, respectively in vertebrate titin,
Figure 1B) have been suggested to preclude kinase activity [114].
This example highlights some of the technical challenges in atyp-
ical kinase and pseudokinase research, as choice of experimental
system and purity of preparations are critical determinants for the
conclusions about potential activity.
IRAKs
IRAKs are a family of serine/threonine kinases with two active
kinases (IRAK1 and 4) and two, likely inactive, pseudokinases
(IRAK2 and 3). IRAK2 functions in the sustained activation of the
Toll-like receptor (TLR) pathway [115], and has been implicated
in colorectal cancer [116] and in the unfolded protein response
[117]. IRAK2 shows cation-dependent nt binding in TSA [9], yet
the molecular details of this are still unclear due to a lack of crys-
tal structures. IRAK2 was shown to have autophosphorylation
activity when immunoprecipitated from activated macrophages,
raising the question of atypical kinase activity despite noncanon-
ical kinase motifs (Gly52, Asp166 and Asp184 missing) [115]. The
kinase activity could, however, only be observed in macrophages
also expressing IRAK4 [115], suggesting that the activity ob-
served was derived from IRAK4, as IRAK2 and IRAK4 interact
in vivo [118]. This would be in line with early results reporting
negligible autophosphorylation activity for recombinant IRAK2
[119].
Whereas IRAKs 1, 2 and 4 are active components of the proin-
flammatory TLR and IL-1R family signalling pathways, IRAK3
(also called IRAK-M) functions as a key modulator of inflam-
matory responses. The expression of IRAK3 is regulated by the
other IRAK members in a negative feedback loop, where IRAK3
associates with the same signalling molecules as IRAK1, 2 and 4
and negatively regulates the pathways [120–122]. Furthermore,
IRAK3 expression is up-regulated by glucocorticoid receptor ac-
tivation, and has been shown to play a key role in the immunosup-
pressive action of glucocorticoids [123]. Recent evidence has also
identified a role for IRAK3 in proinflammatory signalling [122].
The kinase domain of IRAK3 does not show nt binding in TSA
[9], but it evidently has an accessible binding pocket, as it binds
a number of known kinase inhibitors [9,68]. IRAK3 completely
lacks an HRD motif (CGSIRAK3, Figure 1B) and is most likely
an inactive pseudokinase [119], which exerts its function through
non-catalytic mechanisms [121,122].
Alternative catalytic mechanism
WNK, PRPK and Haspin
Some kinases, originally classified as pseudokinases, have later
been found to possess activity via atypical mechanisms. Although
this activity is often low and only detectable in in vitro settings,
biologically significant kinase activity has been established for a
number of PKs initially thought to be inactive. The most prom-
inent example of these is WNK, which is an active kinase where
Lys72 is substituted with a second lysine (Lys233, WNK1) from β2
[27,124]. Interestingly, the unusual position of Lys233, WNK1 has
been proposed to enable WNK1 to bind a halide ion (e.g. Cl− ) at
the back of its nt-binding pocket (Figure 2) [125]. Biochemical
data further suggest that when this ion is present, activation of
WNK1 by autophosphorylation is inhibited, essentially making
WNK1 a chloride sensor. This could explain the apparent regula-
tion by chloride ions observed for WNK1’s downstream targets:
sodium-coupled chloride cotransporters (NCCs) and potassium-
coupled chloride cotransporters (KCCs) [125].
Similarly, p53-related protein kinase (PRPK), a human homo-
logue of yeast Bud32, is catalytically active [126] despite lack-
ing the typical β3 lysine and phosphorylates its only substrate
p53 when pre-phosphorylated by Akt [127]. Another noteworthy
atypical kinase is Haspin, which belongs to its own PKL fam-
ily outside of ePKs [14]. Despite having a modified DFG motif
(DYTHaspin) Haspin is an active kinase [1], contains practically all
catalytically critical residues, and binds ATP in a mostly classical
manner [128].
CONCLUSIONS AND PERSPECTIVES
Most pseudokinases have evolved from active kinases by obtain-
ing regulatory functions where catalytic function is dispensable.
However, a significant proportion of pseudokinases have retained
ATP-binding ability. Presently, detailed and structural informa-
tion exists for only a part of these proteins (Table 1), but mounting
evidence suggests a structurally and functionally important func-
tion for nt binding in several pseudokinases. Indeed, noncatalytic
occupation of the nt-binding pocket is known to regulate multiple
active kinases [129–131], and as pseudokinases share the same
protein fold, similar functional significance for ATP binding can
be expected.
As a structural cofactor, nt binding seems to regulate or enable
acquisition of certain conformations in multiple pseudokinases,
e.g. allowing the domain to adopt a pseudoactive conformation
(like STRADα) by completing the C spine and stabilizing the
domain. Other pseudokinases, like VRK3 or BIR2 (from Ara-
bidopsis), have given up the need for bound nts altogether by
filling out the nt-binding pocket constitutively with bulky amino
acid substitutions (Figure 2). Completion of the spines (R and
C), which is usually predictive of catalytic activity in canonical
kinases [16,30,31], thus cannot be used as a structural predictor of
catalytic activity in pseudokinases, but is still useful in describ-
ing a conformation adopted by a pseudokinase. Furthermore,
most pseudokinases lack the main mode of regulation for active
ePKs, namely a phosphorylated activation loop. Indeed, activ-
ation loops in many pseudokinases are very short to the point
of being practically non-existent. In such an environment, struc-
tural importance of nt-binding pocket occupation in regulation
or modulation of protein–protein interactions could be further
increased.
The binding affinity for ATP is rather low in many pseudok-
inases, which poses technical challenges. However, cellular ATP
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concentrations are in the millimolar range [132], so nt binding
should still occur in a physiological milieu even at relatively
low affinities. Some very low affinity ATP binders (e.g. TRIB2,
CASK) have even been hypothesized to function as cellular nt
concentration sensors [24].
Functional ATP-binding pockets are required for the physiolo-
gical function of multiple pseudokinases, even in the absence of
catalytic activity. The detailed structural consequences of nt oc-
cupation, however, are in many cases not obvious even when
using multiple biophysical methods (e.g. ILK [34]) or when
crystallographic structural data with and without nt are avail-
able (see, e.g. JAK2 JH2 [45]). In these cases methods able to
detect subtle changes in protein dynamics (e.g. NMR or compu-
tational methods) could provide new insights. Nevertheless, in
most cases structure-guided, targeted, carefully controlled muta-
genesis studies, complemented where possible with a chemical
genetics approach [133], are the key to answering questions of
importance of nt-binding pocket occupation.
Pseudokinases play an important regulatory role in cellular
signalling, and abnormal function of several human pseudok-
inases has been associated with human diseases [12]. The most
prominent examples of this are probably the JAK2 JH2 V617F
mutation underlying multiple myeloproliferative neoplasms [64],
and HER3 overexpression in many cancers [134]. In total, over
60 mutations in the human pseudokinome have been shown to
cause, or be linked to, various malignancies [11–13]. With its
direct link to pseudokinase regulatory functions, the nt-binding
site of many pseudokinases poses an interesting option for phar-
macological interventions. For example, the E351K mutation in
MLKL increases affinity for ATP and is associated with hu-
man lung carcinoma [26], and mutations in the ATP-binding
pocket of JAK JH2 revert the hyperactivation of pathogenic JAK
JH2 mutants [45]. To date, only a few pseudokinases, namely
HER3 [135], MLKL [136] and TYK2 [67], have been attemp-
ted to target pharmacologically, providing important proof-of-
principle results that targeting pseudokinases could be a viable
therapeutic option. The results of pharmacological targeting of
MLKL and TYK2 JH2 are significant and encouraging, but it
should be kept in mind that the functions of pseudokinases are
very diverse and not as directly predictable as for active kinases.
Further detailed analysis is required to understand the physiolo-
gical functions of different pseudokinases, and insights thus
gained will lay the basis for potential future therapeutic targeting
attempts.
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